Article Text

Download PDFPDF
P130 Doxorubicin-loaded oligonucleotide conjugated gold nanoparticles: a promising drug delivery system for ovarian cancer
  1. S Jeon and
  2. H Jeon
  1. Soon Chun Hyang University Cheonan Hospital, Cheonan, Republic of Korea


Introduction/Background Major cause of failure in the treatment of advanced ovarian cancer is chemoresistance. Gold nanoparticles(AuNPs) are promising drug delivery systems to overcome chemoresistance. Doxorubicin(DOX) is one of the representative cancer chemotherapeutic agent and is widely used by many researchers as a chemotherapy agent in the drug delivery system, however there have been limited data on ovarian cancer research. Our aim of study was to compare cytotoxic effect between DOX and Doxorubicin loaded oligonucleotides (ONTs) attached to gold nanoparticles (AuNPs) called DOA on ovarian cancer cell lines.

Methodology We propose Doxorubicin loaded oligonucleotides (ONTs) attached to gold nanoparticles (AuNPs) as a drug delivery system for cancer chemotherapy. We utilized AuNPs as drug delivery vehicle, which were synthesized by chemical reduction to be 13 nm diameter. Oligonucleotide - AuNPs present numerous binding sites for DOX, facilitating the delivery of DOX to cancer cells. Transmission electron microscope(TEM), fluorescence spectrometer and MTT assay were done for characterization and for cell viability assay. 증례.

Results We characterization of Doxorubicin-loaded oligonucleotide conjugated gold nanoparticles (DOA) using Transmission electron microscope (TEM) image of AuNPs. (figure 1) And 70% of DOX in solution could be bound to ONTs on AuNPs to became DOX-loaded AuNPs and about 28% of loaded DOX was released from the as-prepared DOA (figure 2). In MTT assay, significant reduction in the cell viability was detected in DOA treated ovarian cancer cells(SKOV3, A2780, Hey A8) than DOX (p<0.05) (figure 3).

Conclusion Our results suggested that ONTs attached AuNP is effective drug delivery system and DOA might be beneficial strategy for chemoresistant patients. We plan to perform in vivo study in the near future for verification from the results from our in vitro study.

Disclosure Nothing to disclose.

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.